Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.61 |
| ▸ | CA1 | P00915 | 13/20 | 0.61 |
| ▸ | CA12 | O43570 | 12/20 | 0.61 |
| ▸ | CA9 | Q16790 | 12/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434012 | 0.87 | CA2 (0.65) | CA2CA1CA12CA9CA14 | |
| SCHEMBL7190905 | 0.84 | PTGS2 (0.45) | CA2CA1CA12CA9ASIC3 | |
| SCHEMBL24257972 | 0.84 | CA1 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL24257965 | 0.77 | CA2 (0.52) | CA2CA1CA12CA9CA14 | |
| SCHEMBL3992333 | 0.76 | CA1 (0.48) | CA2CA1CA12CA9CA14 | |
| SCHEMBL30574457 | 0.75 | MEN1 (0.48) | ASIC3 | |
| SCHEMBL5425213 | 0.75 | ASIC3 (0.62) | CA2CA1CA12CA9CA14 | |
| SCHEMBL21647832 | 0.75 | CA12 (0.39) | CA2CA1CA12CA9ASIC3 | |
| SCHEMBL4802684 | 0.74 | CA1 (0.48) | CA2CA1CA12CA9CA14 | |
| SCHEMBL13959489 | 0.73 | ASIC3 (0.50) | ALOX5ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | CA2 2017/4885CA1 4463/4885CA12 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.